Top Markets
Coin of the day
Molecular Pharmacology (USA), Ltd. Molecular Pharmacology (USA), Ltd.

Molecular Pharmacology (USA), Ltd.

MLPH
주식 순위 #39112
As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is... As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is dedicated to the creation and market introduction of solutions for pain and inflammation, with a primary focus on the Australian and United States markets. Through its subsidiary, Molecular Pharmacology Pty. Ltd., it is advancing an analgesic and anti-inflammatory molecule called Tripeptofen, designed to alleviate common daily pain. These products are offered in diverse dosage forms, formulations, and packaging options to suit various needs. MLPH's marketing strategy involves leveraging pharmaceutical distributors and forging collaborative partnerships with companies in the United States and Europe. Additionally, the company maintains an agreement with Dermatology Development Corporation to jointly develop and market a suite of therapeutic, cosmetic, and cosmeceutical items derived from the ThermaLIFE product line and its core active component. Headquartered in Perth, Australia, Molecular Pharmacology (USA) Limited operates as a subsidiary of PharmaNet Group Limited.
주가
$0.0322
마지막 동기화: 2026-08-12
시가총액
$643.71K
변동 (1일)
0.00%
변동 (1년)
544.00%
국가
AU
거래 Molecular Pharmacology (USA), Ltd. (MLPH)

카테고리

Molecular Pharmacology (USA), Ltd. (MLPH)의 수익
2026 기준 수익 TTM: 0
Molecular Pharmacology (USA), Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 수익 0과 동일입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Molecular Pharmacology (USA), Ltd.의 수익 기록 (2026 ~ 2026)
연말 수익
연도 수익 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
$5.27B -
US
$1.95B -
NL
- -
CH
- -
KR
$3.01B -
BE